Advertisement

Search Results

Advertisement



Your search for all items matches 33446 pages

Showing 351 - 400


Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, Joins Perthera as Chief Medical Officer

Perthera, an industry leader in precision oncology decision support, recently announced that Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, joined Perthera as Chief Medical Officer. Dr. Raghavan is founding President of the Levine Cancer Institute and former Chair and Director of the Cleveland...

survivorship

Apply Through July 31, 2024, for Survivorship Champion’s Prize

Children’s Cancer Cause, a national advocacy group in pioneering research and innovation for pediatric cancer, announced it is accepting applications for the Survivorship Champion’s Prize. This award is presented to a group, program, or institution that has demonstrated significant advancements in...

gynecologic cancers

Influence of Menopausal Hormone Therapy on Gynecologic Cancer Incidence and Mortality

In 2002, the federally funded Women’s Health Initiative—a randomized, placebo-controlled clinical trial investigating the effects of menopausal hormone therapy in healthy menopausal women—was abruptly halted when it was determined that taking estrogen and progestin hormones after menopause...

survivorship

Study Explores How Partner Relationships Impact the Well-Being of Breast Cancer Survivors

Diagnosis and treatment of breast cancer place significant stress on survivors, their partners, and their relationships. A recent study from researchers at the Regenstrief Institute and Indiana University (IU)’s Schools of Nursing, Science, and Medicine is one of the first to examine the impact of...

lung cancer

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK-Positive NSCLC

As reported in The New England Journal of Medicine by Yi‑Long Wu, MD, of Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and colleagues, the phase III ALINA trial has shown significantly improved disease-free survival with adjuvant alectinib vs platinum-based chemotherapy...

gynecologic cancers

Noninferiority of Simple vs Radical Hysterectomy for Pelvic Recurrence in Low-Risk Cervical Cancer

As reported in The New England Journal of Medicine by Marie Plante, MD, of Centre Hospitalier Universitaire de Quebec, and colleagues, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in the frequency of pelvic recurrence in women with low-risk cervical...

issues in oncology

Understanding the Legal and Ethical Challenges AI Poses in Oncology

The field of oncology is experiencing a revolution driven by artificial intelligence (AI) technology. Artificial intelligence tools are already being used in medical imaging analysis, treatment planning, and even patient counseling. These advancements hold immense promise for earlier cancer...

lung cancer

Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC

As reported in the Journal of Clinical Oncology by Joel Neal, MD, PhD, and colleagues, the phase III CONTACT-01 trial has shown no significant improvement in overall survival with the tyrosine kinase inhibitor atezolizumab (multiple targets, including MET, AXL, VEGFR2, RET, and FLT) plus the...

breast cancer

USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer

On April 30, 2024, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer.1 The USPSTF now recommends that all women undergo screening for breast cancer every other year starting at age 40 and continuing through age 74. More...

breast cancer

Novel Approaches Show Early Activity in Endocrine-Resistant Breast Cancer

For breast cancer that is estrogen receptor–positive, CDK4/6 inhibitors, given with endocrine therapy, have become the standard of care, especially in metastatic disease. However, resistance to both endocrine therapies and CDK4/6 inhibitors is common, and new approaches are needed to counteract...

issues in oncology

HPV Vaccine Shows Prevention Efficacy for Several Types of HPV-Related Cancers in Both Males and Females

According to the Centers for Disease Control and Prevention, since the human papillomavirus (HPV) vaccine was introduced in the United States in 2006, HPV infections that cause most HPV-related cancers and genital warts have decreased by 88% among teenage girls and 81% among young adult women. Now, ...

breast cancer
survivorship

Most Breast Cancer Survivors Able to Achieve Pregnancy After Diagnosis, Study Finds

Research examining fertility preservation and pregnancy attempts among young women following a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of pregnancy attempts. A new long-term study investigating fertility outcomes among young women who...

breast cancer

Use of Topical Diclofenac Gel to Prevent Capecitabine-Associated Hand-Foot Syndrome

In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that the nonsteroidal, anti-inflammatory topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast ...

kidney cancer
immunotherapy

CRISPR-Edited, Off-the-Shelf CAR T-Cell Therapy Shows Proof of Concept in Renal Cell Carcinoma

Evidence from a small early trial called COBALT-RCC provides proof of concept for use of an allogeneic off-the-shelf CD70-targeted chimeric antigen receptor (CAR) T-cell therapy called CTX130 in patients with advanced clear cell renal cell carcinoma (RCC). CTX130 is engineered using gene-editing...

issues in oncology

Study Finds the Financial Hardship Caused by Cancer Is Long-Lasting for Many Working-Age Adults

When combined with high out-of-pocket costs for cancer care, nearly 60% of working-age cancer survivors report experiencing at least one type of financial hardship, including being unable to afford medical bills, distress and worry, or delaying or forgoing needed care because of cost, according to...

bladder cancer

Pembrolizumab in High-Risk Non–Muscle-Invasive Bladder Cancer

As reported in The Lancet Oncology by Andrea Necchi, MD, and colleagues, findings in cohort B of the phase II KEYNOTE-057 study indicated that pembrolizumab was active in patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle invasive bladder cancer.  As noted by the...

gynecologic cancers

HPV Screening Intervals for Cervical Cancer May Be Safely Extended Beyond Current 5-Year Recommendation, Study Finds

A longitudinal cohort study published by Gottschlich et al in Cancer Epidemiology, Biomarkers & Prevention investigated the optimal interval between screening tests and the long-term risk of cervical precancer or worse (CIN2+). Researchers found that the risk of cervical precancer 8 years after ...

hepatobiliary cancer

FDA Withdraws Approval of Cholangiocarcinoma Drug Indication for FGFR Inhibitor

On May 16, the U.S. Food and Drug Administration (FDA) announced the final withdrawal of the approval of infigratinib (Truseltiq) for previously treated patients with unresectable, locally advanced, or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other...

colorectal cancer
issues in oncology

Survival Outcomes Following Adjuvant Therapy in Patients With Clinical T2N0 Rectal Adenocarcinoma

Adjuvant therapy may be underutilized in patients with clinical T2N0 rectal adenocarcinoma, according to new findings presented by Kripalani et al at Digestive Disease Week (DDW) 2024 (Abstract 439). Background Patients with clinical T2N0 rectal adenocarcinoma have disease that has spread past the...

prostate cancer
issues in oncology

Sexual Well-Being in the Female Partners of Patients With Prostate Cancer

The female partners of patients with prostate cancer may experience quality-of-life issues that impact their sexual well-being, according to a recent study published by Loeb et al in European Urology Oncology. Background Prostate cancer—one of the most common cancer types in U.S. men—and its...

hepatobiliary cancer

Gallbladder Cancer Rates Among Black Patients in the United States

Gallbladder cancer rates have been stable or declining for most Americans over the past two decades, but cases have steadily risen among Black Americans, with growing numbers of cases not being diagnosed until later disease stages, according to a study presented at Digestive Disease Week 2024...

issues in oncology

Outcomes for Cancer Drugs Initially FDA-Approved With Immature Overall Survival Data

In a study reported in The Lancet Oncology, Naci et al identified the degree to which initial U.S. Food and Drug Administration (FDA) approvals of cancer drugs based on immature overall survival data were subsequently followed by reporting of overall survival results. Study Details The study...

solid tumors
genomics/genetics
issues in oncology

Onychopapilloma May Be Linked to BAP1 Tumor Predisposition Syndrome

Researchers have discovered that the presence of a benign nail condition known as onychopapilloma may lead to the diagnosis of BAP1 tumor predisposition syndrome, according to a recent study presented by Lebensohn et al at the Society for Investigative Dermatology 2024 Annual Meeting and...

hematologic malignancies
issues in oncology

Metformin May Help Reduce the Risk of Developing Myeloproliferative Neoplasms

Treatment with metformin may be associated with a lower risk of developing myeloproliferative neoplasms over time, according to a recent study published by Kristensen et al in Blood Advances. Background Myeloproliferative neoplasms are a group of diseases that develop over long periods of time and...

gastroesophageal cancer
gastrointestinal cancer

Advanced Gastric or Gastroesophageal Junction Cancer: Addition of Relatlimab to Immunochemotherapy

In the phase II RELATIVITY-060 study, results of which were reported in the Journal of Clinical Oncology, Susanna Hegewisch-Becker, MD, PhD, and colleagues found that the addition of the LAG-3–blocking antibody relatlimab to first-line nivolumab plus chemotherapy did not improve the objective...

multiple myeloma

Linvoseltamab Achieves High Response Rates in Relapsed or Refractory Myeloma

The investigational bispecific antibody linvoseltamab (targeting B-cell maturation antigen [BCMA] and CD3) achieved high response rates with acceptable safety in heavily pretreated patients with relapsed or refractory multiple myeloma, according to results of the phase I/II LINKER-MM1 study...

lung cancer

Adding Perioperative Nivolumab to Neoadjuvant Chemotherapy in Resectable NSCLC: CheckMate 77T

As reported in The New England Journal of Medicine by Tina Cascone, MD, PhD, and colleagues, interim analysis in the phase III CheckMate 77T trial has shown that the addition of perioperative nivolumab to neoadjuvant chemotherapy improved event-free survival in patients with resectable non–small...

bladder cancer
immunotherapy

Nivolumab/Ipilimumab Boost in Metastatic Urothelial Carcinoma

In a German-Austrian phase II study (TITAN-TCC) reported in JAMA Oncology, Grimm et al described outcomes with the use of nivolumab plus ipilimumab as an immunotherapeutic boost in metastatic urothelial carcinoma. Study Details In the multicenter trial, 169 patients were enrolled into two cohorts...

hepatobiliary cancer

Pertuzumab Plus Trastuzumab for Advanced Biliary Tract Cancer With HER2/3 Alterations

As reported in the Journal of Clinical Oncology by Cannon et al, findings in a cohort of the phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket study showed that the combination of pertuzumab and trastuzumab was active in patients with advanced biliary tract cancer with...

multiple myeloma
breast cancer
bladder cancer
gynecologic cancers
skin cancer
pancreatic cancer

NCCN Clinical Practice Guidelines in Oncology: 2024 Updates

The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...

solid tumors
issues in oncology

End-of-Life Systemic Therapy May Not Improve Survival in Patients With Advanced Solid Tumors

Systemic therapy may offer no significant improvement in overall survival in patients with advanced solid tumors, according to a recent study published by Canavan et al in JAMA Oncology. Study Methods and Results In the recent study, the investigators analyzed the de-identified data of over 78,000...

breast cancer
issues in oncology
supportive care

Bariatric Surgery May Help Reduce the Risk of Breast Cancer in Female Patients With Obesity, Hyperinsulinemia

Bariatric surgery may be associated with a reduced risk of breast cancer in female patients with obesity, especially those with hyperinsulinemia at the time of surgery, according to a recent study published by Kristensson et al in JAMA Surgery. Bariatric surgery is known to be one of the most...

multiple myeloma

Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival?

Results from the Prognostic Immunophenotyping in Myeloma Response (PRIMeR) study, reported in the Journal of Clinical Oncology by Marcelo C. Pasquini, MD, MS, and colleagues, found that undetectable measurable residual disease (MRD) status at 1 year after autologous hematopoietic cell...

gastroesophageal cancer

Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer: Comparison of Agents

In a Chinese phase III trial (CRTCOESC) reported in the Journal of Clinical Oncology, Jia et al found that neither capecitabine nor XELOX (capecitabine, oxaliplatin) improved 2-year overall survival vs cisplatin/fluorouracil as part of definitive concurrent chemoradiotherapy in patients with...

lung cancer

FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC

On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tarlatamab-dlle (Imdelltra), a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, for patients with extensive-stage small cell lung cancer (SCLC) with disease progression on or after...

leukemia
issues in oncology

Half-Matched Family Donors May Improve ASCT Outcomes in Hispanic Patients With ALL

Researchers have found that allogeneic stem cell transplantation from a haploidentical relative may significantly increase the rate of success in Hispanic patients with acute lymphoblastic leukemia (ALL), according to a recent study published by Ashouri et al in Leukemia Research. Background In...

breast cancer
issues in oncology

Childhood Adiposity and Risk for Breast Cancer

Investigators have uncovered that a higher adiposity in childhood may lead to less dense tissue formation and decrease the risk of breast cancer, according to a recent study published by Vabistsevits et al in Nature Communications. Background As a result of the rising incidence of breast cancer,...

breast cancer
supportive care
survivorship

Donepezil for the Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy

In the phase III WF-97116 trial reported in the Journal of Clinical Oncology, Rapp et al found that treatment with the cognitive enhancer donepezil did not improve memory or other cognitive functions vs placebo in breast cancer survivors with cancer-related cognitive impairment 1 to 5 years after...

palliative care

Providing Culturally Sensitive Palliative Care to Children With Cancer

In the fall of 2023, Justin Baker, MD, took on the role of Chief of the Division of Quality of Life and Pediatric Palliative Care and Director of the Quality of Life for All Program, Stanford Medicine Children’s Health, Stanford, California. He formerly worked at St. Jude Children’s Research...

Daniel M. Geynisman, MD, Named New JNCCN Editor-in-Chief

Daniel M. Geynisman, MD, has been announced as the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. Dr. Geynisman is Associate Professor in the Department of Hematology/Medical Oncology and Chief of the Division of Genitourinary Medical Oncology at Fox Chase...

lymphoma
immunotherapy

FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma

On May 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic...

breast cancer
genomics/genetics

Newly Identified Genetic Variants Linked to Breast Cancer Risk in Women of African Ancestry

Researchers have uncovered novel genetic variants potentially associated with a higher risk of breast cancer–related mortality among women of African ancestry, according to a recent study published by Jia et al in Nature Genetics. Background Breast cancer is the most common type of cancer among...

prostate cancer
supportive care

Plant-Based Diet May Offer Benefit in Patients With Prostate Cancer

A plant-based diet may help reduce the risk of disease progression in patients with prostate cancer, according to a recent study published by Liu et al in JAMA Network Open. Background Prostate cancer is the most common type of cancer among men. Plant-based diets—which are becoming increasingly...

lymphoma

Third-Line Therapy for Transplant-Ineligible DLBCL

This is Part 3 of Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Jason Westin, Dai Chihara, and Caron A. Jacobson discuss the third-line treatment of...

lymphoma

Late Relapsing DLBCL

This is Part 2 of Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Jason Westin, Dai Chihara, and Caron A. Jacobson discuss the treatment of late...

lymphoma

Early Relapsed/Refractory DLBCL

This is Part 1 of Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Jason Westin, Dai Chihara, and Caron A. Jacobson discuss the treatment of early...

issues in oncology

AACR Cancer Disparities Progress Report 2024 Highlights Ongoing Health Inequities Experienced by Racial and Ethnic Minorities

Despite the extraordinary progress against cancer in the United States—illustrated by the continuing decline in the overall mortality rate, which fell by 33% between 1991 and 2020, and the increasing numbers of cancer survivors (over 18 million and climbing)—the burden of cancer remains...

lymphoma

Previously Untreated Mantle Cell Lymphoma: Ibrutinib, Immunochemotherapy, and ASCT

As reported in The Lancet by Martin Dreyling, MD, PhD, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell transplantation (ASCT) significantly improved failure-free...

kidney cancer

Marker for Distinguishing Renal Cell Carcinoma From Benign Renal Masses

In a study reported in the Journal of Clinical Oncology, Xu et al found that higher levels of preoperative plasma kidney injury molecule-1 (pKIM-1) distinguished renal cell carcinoma from benign renal masses. As stated by the investigators, “Both clear cell and papillary renal cell carcinoma...

gynecologic cancers
head and neck cancer
colorectal cancer

FDA Approves HPV Self-Collection Solution

On May 15, Roche announced the U.S. Food and Drug Administration (FDA) approval of its human papillomavirus (HPV) self-collection solution—one of the first of such tests available in the United States. Screening for HPV can help identify women who are at risk of developing cervical cancer so that...

Advertisement

Advertisement




Advertisement